The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | MRD in WM: its potential in guiding treatment decisions and as a surrogate endpoint in trials
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the importance of measurable residual disease (MRD) in Waldenström’s macroglobulinemia (WM). He references the BRAWM study (NCT04624906) as evidence for using MRD in WM and discusses the potential of using MRD to guide treatment decisions and as a surrogate endpoint in clinical trials. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
